Biohaven’s bid to bring to market the first drug for rare neuromuscular disorder spinocerebellar ataxia has hit a setback. The FDA is refusing to review the drug’s application, a decision that could indicate the agency wants another clinical trial.
Biohaven Ltd. (NYSE:BHVN – Get Free Report) traded down 2.8% during mid-day trading on Monday . The stock traded as low as $24.72 and last traded at $24.72. 100,080 shares changed hands during trading, a decline of 90% from the average session volume of 984,820 shares. The stock had previously closed at $25.44. Analyst Upgrades […]
Biohaven Ltd. (NYSE:BHVN – Get Rating) saw a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 6,060,000 shares, a decrease of 11.8% from the May 15th total of 6,870,000 shares. Currently, 10.4% of the company’s shares are short sold. Based on an average daily […]
Biohaven Ltd. (NYSE:BHVN – Get Rating)’s stock price shot up 6.6% during mid-day trading on Wednesday . The company traded as high as $17.42 and last traded at $17.36. 1,464,527 shares were traded during trading, an increase of 59% from the average session volume of 923,456 shares. The stock had previously closed at $16.28. Analyst […]
Biohaven Ltd. (NYSE:BHVN – Get Rating) shot up 6.6% during mid-day trading on Wednesday . The stock traded as high as $17.42 and last traded at $17.36. 1,464,527 shares were traded during trading, an increase of 59% from the average session volume of 923,456 shares. The stock had previously closed at $16.28. Wall Street Analysts […]